Shortened LSD Intervention for Major Depressive Disorder

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT07503002
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Major Depression
  • Major Depression Moderate
  • Major Depression Severe

Eligibility Criteria

Sex
ALL
Age
21 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • LSD — DRUG
    Participants will be administered LSD followed 45-minutes later by risperidone.
  • Risperidone — DRUG
    Participants will be administered LSD followed 45-minutes later by risperidone.

Study Details

The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.

Key Dates

Start date
Jul 1, 2026
Status verified
Mar 2026
Primary completion
Jul 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LSD + Risperidone

Primary Outcome Measure

Change in Montgomery Asberg Depression Rating Scale (MADRS) [ Time Frame: 1 month ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimoreMaryland21224
Matthew Nielsen, BA
[email protected]
917-991-0642
Sandeep Nayak, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

By research site
Johns Hopkins Center for Psychedelic and Consciousness Research· Baltimore, MD

Related Studies